226 related articles for article (PubMed ID: 17383385)
1. Postoperative coagulopathy in a pediatric patient after exposure to bovine topical thrombin.
Crow SS; Sullivan VV; Aysola AE; Key NS; Harker-Murray P; Foker JE; Steiner ME
Ann Thorac Surg; 2007 Apr; 83(4):1547-9. PubMed ID: 17383385
[TBL] [Abstract][Full Text] [Related]
2. Acquired coagulation factor inhibitors in children after topical bovine thrombin exposure.
Savage WJ; Kickler TS; Takemoto CM
Pediatr Blood Cancer; 2007 Dec; 49(7):1025-9. PubMed ID: 16526049
[TBL] [Abstract][Full Text] [Related]
3. Development of antibodies to human thrombin and factor V in a pediatric patient exposed to topical bovine thrombin.
Lo CY; Jones C; Glader B; Zehnder JL
Pediatr Blood Cancer; 2010 Dec; 55(6):1195-7. PubMed ID: 20979176
[TBL] [Abstract][Full Text] [Related]
4. Immune-mediated coagulopathy: a case report.
Naoum JJ
Pharmacotherapy; 2009 Jul; 29(7 Pt 2):13S-7S. PubMed ID: 19558280
[TBL] [Abstract][Full Text] [Related]
5. Immune-mediated coagulopathy associated with topical bovine thrombin: review of the pediatric literature.
Rodgers GM
J Pediatr Hematol Oncol; 2011 Mar; 33(2):86-8. PubMed ID: 21228719
[TBL] [Abstract][Full Text] [Related]
6. Redo cardiac surgery: late bleeding complications from topical thrombin-induced factor V deficiency.
Cmolik BL; Spero JA; Magovern GJ; Clark RE
J Thorac Cardiovasc Surg; 1993 Feb; 105(2):222-7; discussion 227-8. PubMed ID: 8429648
[TBL] [Abstract][Full Text] [Related]
7. Re-operative surgery in pediatric patients.
Delius RE; Walters HL
Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu; 2003; 6():108-15. PubMed ID: 12740777
[TBL] [Abstract][Full Text] [Related]
8. Factor V inhibitor after injection of human thrombin (tissucol) into a bleeding peptic ulcer.
Caers J; Reekmans A; Jochmans K; Naegels S; Mana F; Urbain D; Reynaert H
Endoscopy; 2003 Jun; 35(6):542-4. PubMed ID: 12783357
[TBL] [Abstract][Full Text] [Related]
9. Bovine thrombin induces an acquired coagulopathy in sensitized patients undergoing revision spinal surgery: a report of two cases.
Poynton AR; Nelson MC; McCance SE; Levine RL; O'Leary PF
Spine (Phila Pa 1976); 2003 Jun; 28(12):E221-3. PubMed ID: 12811284
[TBL] [Abstract][Full Text] [Related]
10. Development of antibodies to topical bovine thrombin after abdominal hysterectomy. A case report.
Adams JD; Jones S; Brost BC
J Reprod Med; 2001 Oct; 46(10):909-12. PubMed ID: 11725736
[TBL] [Abstract][Full Text] [Related]
11. Development of factor V and thrombin inhibitors in children following bovine thrombin exposure during cardiac surgery: a report of three cases.
Bomgaars L; Carberry K; Fraser C; West A; Teruya J
Congenit Heart Dis; 2010; 5(3):303-8. PubMed ID: 20576051
[TBL] [Abstract][Full Text] [Related]
12. Coagulopathy as a result of factor V inhibitor after exposure to bovine topical thrombin.
Neschis DG; Heyman MR; Cheanvechai V; Benjamin ME; Flinn WR
J Vasc Surg; 2002 Feb; 35(2):400-2. PubMed ID: 11854743
[TBL] [Abstract][Full Text] [Related]
13. Bovine thrombin-induced inhibitor of factor V and bleeding risk in postoperative neurosurgical patients. Report of three cases.
Spero JA
J Neurosurg; 1993 May; 78(5):817-20. PubMed ID: 8468613
[TBL] [Abstract][Full Text] [Related]
14. Risks and predictors of blood transfusion in pediatric patients undergoing open heart operations.
Székely A; Cserép Z; Sápi E; Breuer T; Nagy CA; Vargha P; Hartyánszky I; Szatmári A; Treszl A
Ann Thorac Surg; 2009 Jan; 87(1):187-97. PubMed ID: 19101294
[TBL] [Abstract][Full Text] [Related]
15. Severe bleeding due to factor V inhibitor after repeated operations using fibrin sealant containing bovine thrombin.
Muntean W; Zenz W; Edlinger G; Beitzke A
Thromb Haemost; 1997 Jun; 77(6):1223. PubMed ID: 9241765
[No Abstract] [Full Text] [Related]
16. Acquired factor V inhibitor: a common and avoidable complication of topical bovine thrombin application.
Kirkeby KM; Aronowitz P
Am J Med; 2005 Jul; 118(7):805. PubMed ID: 15989925
[No Abstract] [Full Text] [Related]
17. Thrombin products: economic impact of immune-mediated coagulopathies and practical formulary considerations.
Voils SA
Pharmacotherapy; 2009 Jul; 29(7 Pt 2):18S-22S. PubMed ID: 19558281
[TBL] [Abstract][Full Text] [Related]
18. Antihuman factor V antibodies after use of relatively pure bovine thrombin.
Lawson JH; Lynn KA; Vanmatre RM; Domzalski T; Klemp KF; Ortel TL; Niklason LE; Parker W
Ann Thorac Surg; 2005 Mar; 79(3):1037-8. PubMed ID: 15734434
[TBL] [Abstract][Full Text] [Related]
19. Anatomical model at risk of coarctation of the pulmonary artery.
Troise DE; Guarnieri GF; Balducci G; Tagliente MR; Arciprete PM; Schinosa Lde L
Ann Thorac Surg; 2008 Apr; 85(4):1505; author reply 1506. PubMed ID: 18355579
[No Abstract] [Full Text] [Related]
20. Immunization by bovine thrombin used with fibrin glue during cardiovascular operations. Development of thrombin and factor V inhibitors.
Berruyer M; Amiral J; Ffrench P; Belleville J; Bastien O; Clerc J; Kassir A; Estanove S; Dechavanne M
J Thorac Cardiovasc Surg; 1993 May; 105(5):892-7. PubMed ID: 8487567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
